Benefit of intravitreal injections in patients with sub-threshold baseline visual acuity: a retrospective single-centre study

[1]  U. Schmidt-Erfurth,et al.  Impact of intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial. , 2021, Ophthalmology. Retina.

[2]  H. Hoerauf,et al.  Das modifizierte Treat-and-Extend-Schema mit Injektionsblöcken in der IVOM-Therapie , 2020, Der Ophthalmologe.

[3]  Rishi P. Singh,et al.  HAWK and HARRIER: 96-Week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. , 2020, Ophthalmology.

[4]  D. Gesellschaft,et al.  Stellungnahme der DOG, der RG und des BVA zur Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration , 2020, Klinische Monatsblätter für Augenheilkunde.

[5]  D. Gesellschaft,et al.  Stellungnahme der DOG, der RG und des BVA zur Therapie des diabetischen Makulaödems , 2020, Klinische Monatsblätter für Augenheilkunde.

[6]  U. Schmidt-Erfurth,et al.  HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. , 2019, Ophthalmology.

[7]  P. Kaiser,et al.  Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. , 2016, Ophthalmology.

[8]  Markus Pauly,et al.  Rank‐based procedures in factorial designs: hypotheses about non‐parametric treatment effects , 2016, 1606.03973.

[9]  S. Androudi,et al.  Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts , 2016, Advances in Therapy.

[10]  F. Holz,et al.  Design des ORCA-Moduls der OCEAN-Studie , 2016, Der Ophthalmologe.

[11]  P. Campochiaro,et al.  Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. , 2016, Ophthalmology.

[12]  P. Kaiser,et al.  Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. , 2015, Ophthalmology.

[13]  S. Fauser,et al.  Retrospektive Untersuchung der Anti-VEGF-Behandlungsrealität und Wirksamkeit bei Patienten mit neovaskulärer altersabhängiger Makuladegeneration (nAMD) in Deutschland , 2015, Der Ophthalmologe.

[14]  U. Schmidt-Erfurth,et al.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. , 2014, American journal of ophthalmology.

[15]  P. Kaiser,et al.  Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.

[16]  S. Whitcup,et al.  Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. , 2014, Ophthalmology.

[17]  Francesco Bandello,et al.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) , 2014, British Journal of Ophthalmology.

[18]  J. Haller,et al.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. , 2014, Ophthalmology.

[19]  U. Schmidt-Erfurth,et al.  Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. , 2014, Ophthalmology.

[20]  Q. Nguyen,et al.  Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. , 2013, Ophthalmology.

[21]  J. Haller,et al.  Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. , 2013, American journal of ophthalmology.

[22]  Y. Ogura,et al.  VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study , 2013, British Journal of Ophthalmology.

[23]  Christian Simader,et al.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.

[24]  Quan Dong Nguyen,et al.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.

[25]  Mitteilungen der DOG , 2012, Der Ophthalmologe.

[26]  Francesco Bandello,et al.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.

[27]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[28]  P. Campochiaro,et al.  Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[29]  Mark Michels,et al.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.

[30]  M. Bach,et al.  Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT) , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[31]  Michael Bach,et al.  Visual acuities "hand motion" and "counting fingers" can be quantified with the freiburg visual acuity test. , 2006, Investigative ophthalmology & visual science.

[32]  L. Knudsen.  Visual acuity testing in diabetic subjects: the decimal progression chart versus the Freiburg visual acuity test , 2003, Graefe's Archive for Clinical and Experimental Ophthalmology.

[33]  Ulrike Willinger,et al.  Eine neue Lesetafel* zur gleichzeitigen Bestimmung von Lesevisus und Lesegeschwindigkeit , 1998 .